Shots: 

• The P-II COMPARE study assessing SEL-212 (once monthly) vs pegloticase (twice monthly) in 170 patients with chronic refractory gout
• SEL-212 showed a numerically higher response rate on 1EP during 3 & 6 mos.- but didn’t meet 1EP of superiority- higher response rate during 3 & 6mos.- an overall reduction in mean SUA levels; patients with tophi at baseline showed higher responder rates with a reduction in mean SUA and is well tolerated
• SEL-212 is a combination product candidate designed to sustain control SUA levels in patients with chronic refractory gout- potentially reducing harmful tissue urate deposits. The companies also initiate the P-III studies (DISSOLVE I& II) of SEL-212 for chronic refractory gout with its expected results in H2’22 and BLA filing in Q3’23

­ Ref: PRNewswire | Image: Mynewsdesk